Back to Search Start Over

Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry

Authors :
Jose-Manuel Ramos-Rincon
María-Dolores López-Carmona
Lidia Cobos-Palacios
Almudena López-Sampalo
Manuel Rubio-Rivas
María-Dolores Martín-Escalante
Santiago de-Cossio-Tejido
María-Luisa Taboada-Martínez
Antonio Muiño-Miguez
Maria Areses-Manrique
Carmen Martinez-Cilleros
Carlota Tuñón-de-Almeida
Lucy Abella-Vázquez
Angel-Luís Martínez-Gonzalez
Luis-Felipe Díez-García
Carlos-Jorge Ripper
Victor Asensi
Angeles Martinez-Pascual
Pablo Guisado-Vasco
Carlos Lumbreras-Bermejo
Ricardo Gómez-Huelgas
on behalf of the SEMI-COVID-19 Network
Source :
Journal of Clinical Medicine, Vol 11, Iss 13, p 3769 (2022)
Publication Year :
2022
Publisher :
MDPI AG, 2022.

Abstract

(1) Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19; (2) Methods: This is a retrospective analysis of patients ≥ 80 years hospitalized in Spain between 15 July and 31 December 2020 (SEMI-COVID-19 Registry). Differences in 30-day all-cause mortality were adjusted using a multivariable regression analysis. (3) Results: Of the 4331 patients admitted, 1312 (30.3%) were ≥80 years. Very old patients treated with remdesivir (n: 140, 10.7%) had a lower mortality rate than those not treated with remdesivir (OR (95% CI): 0.45 (0.29–0.69)). After multivariable adjustment by age, sex, and variables associated with lower mortality (place of COVID-19 acquisition; degree of dependence; comorbidities; dementia; duration of symptoms; admission qSOFA; chest X-ray; D-dimer; and treatment with corticosteroids, tocilizumab, beta-lactams, macrolides, and high-flow nasal canula oxygen), the use of remdesivir remained associated with a lower 30-day all-cause mortality rate (adjusted OR (95% CI): 0.40 (0.22–0.61) (p < 0.001)). (4) Conclusions: Remdesivir may reduce mortality in very old patients hospitalized with COVID-19.

Details

Language :
English
ISSN :
20770383
Volume :
11
Issue :
13
Database :
Directory of Open Access Journals
Journal :
Journal of Clinical Medicine
Publication Type :
Academic Journal
Accession number :
edsdoj.37c49a167a9e4b41a39629cae2260854
Document Type :
article
Full Text :
https://doi.org/10.3390/jcm11133769